Martijn Simons
0000-0001-5248-1676
Pharmerit (Netherlands)
10 papers found
Refreshing results…
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients
Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
Early technology assessment of using whole genome sequencing in personalized oncology
Whole genome sequencing in oncology: using scenario drafting to explore future developments
Early technology assessment of using whole genome sequencing in personalised oncology.
Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review
Missing publications? Search for publications with a matching author name.